| 摘要: |
| ［摘要］ 目的 探讨布地奈德福莫特罗联合茶碱缓释片和孟鲁司特钠治疗中重度支气管哮喘缓解期的临床疗效。方法 选择该院2015-02～2016-07收治的缓解期支气管哮喘患者112例作为研究对象，随机分为对照组和观察组各56例。对照组予以孟鲁司特钠联合茶碱缓释片治疗，观察组予以布地奈德福莫特罗联合茶碱缓释片和孟鲁司特钠治疗，两组均治疗2周。对比两组治疗前后的炎症因子水平及肺功能。结果 治疗前，两组炎症因子水平及肺功能差异无统计学意义（P>0.05）。治疗后观察组的白细胞介素-4（IL-4）、白细胞介素-5（IL-5）及肿瘤坏死因子-α（TNF-α）水平均低于对照组，第1秒用力呼气容积（FEV1）、用力肺活量（FVC）及1秒钟用力呼气容积占用力肺活量的百分比（FEV1/FVC）均高于对照组，差异具有统计学意义（P<0.01）。结论 对缓解期支气管哮喘患者予以布地奈德福莫特罗联合茶碱缓释片和孟鲁司特钠治疗效果确切，对减轻患者的炎症反应、增强肺功能具有积极的意义。 |
| 关键词: 布地奈德福莫特罗 茶碱缓释片 孟鲁司特钠 中重度支气管哮喘 缓解期 |
| DOI：10.3969/j.issn.1674-3806.2017.08.23 |
| 分类号:R 65 |
| 基金项目: |
|
| Clinical observation on budesonide formoterol combined with theophylline sustained release tablets and montelukast sodium in treatment of moderate to severe bronchial asthma in remission stage |
|
ZHANG Lian-guo
|
|
Clinical observation on budesonide formoterol combined with theophylline sustained release tablets and montelukast sodium in treatment of moderate to severe bronchial asthma in remission stage
|
| Abstract: |
| ［Abstract］ Objective To investigate the clinical efficacy of budesonide formoterol combined with theophylline sustained release tablets and montelukast sodium in treatment of moderate to severe bronchial asthma in remission stage.Methods 112 patients with moderate to severe bronchial asthma in remission stage in our hospital from February 2015 to July 2016 were randomly divided into two groups, with 56 cases in each group. The control group received montelukast sodium combined with theophylline sustained release tablets, while the observation group was treated with budesonide formoterol combined with theophylline sustained release tablets and montelukast sodium. Both of the two groups were given the treatment for two weeks. Before and after the treatment, the levels of inflammatory factors and lung function were compared between the two groups.Results Before the treatment, there were no significant differences in the levels of inflammatory factors and lung function between the two groups(P>0.05). After the treatment, the levels of interleukin-4(IL-4), interleukin-5(IL-5) and tumor necrosis factor-α(TNF-α) in the observation group were lower than those in the control group. The forced expiratory volume in one second(FEV1), forced vital capacity(FVC) and FEV1/FVC in the observation group were higher than those in the control group(P<0.01).Conclusion Budesonide formoterol combined with theophylline sustained release tablets and montelukast sodium is effective in the treatment of moderate to severe bronchial asthma in remission stage, which can reduce the inflammatory reaction and increase the lung function. |
| Key words: Budesonide formoterol Theophylline sustained release tablets Montelukast sodium Moderate to severe bronchial asthma Remission stage |
